115 related articles for article (PubMed ID: 6257497)
1. des-Ser2 salmon calcitonin: a biologically potent synthetic analog.
Schwartz KE; Orlowski RC; Marcus R
Endocrinology; 1981 Mar; 108(3):831-5. PubMed ID: 6257497
[TBL] [Abstract][Full Text] [Related]
2. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
Orlowski RC; Epand RM; Stafford AR
Eur J Biochem; 1987 Jan; 162(2):399-402. PubMed ID: 3803393
[TBL] [Abstract][Full Text] [Related]
3. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
Epand RM; Epand RF; Stafford AR; Orlowski RC
J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
[TBL] [Abstract][Full Text] [Related]
4. A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats.
Yates AJ; Gutierrez GE; Garrett IR; Mencel JJ; Nuss GW; Schreiber AB; Mundy GR
Endocrinology; 1990 Jun; 126(6):2845-9. PubMed ID: 2351097
[TBL] [Abstract][Full Text] [Related]
5. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
6. Biological activities and receptor interactions of des-Leu16 salmon and des-Phe16 human calcitonin.
Findlay DM; Michelangeli VP; Orlowski RC; Martin TJ
Endocrinology; 1983 Apr; 112(4):1288-91. PubMed ID: 6299689
[TBL] [Abstract][Full Text] [Related]
7. Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes.
Twery MJ; Seitz PK; Nickols GA; Cooper CW; Gallagher JP; Orlowski RC
Eur J Pharmacol; 1988 Oct; 155(3):285-92. PubMed ID: 3266153
[TBL] [Abstract][Full Text] [Related]
8. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions.
Stroop SD; Nakamuta H; Kuestner RE; Moore EE; Epand RM
Endocrinology; 1996 Nov; 137(11):4752-6. PubMed ID: 8895343
[TBL] [Abstract][Full Text] [Related]
9. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
10. Age-related change in parathyroid hormone-dependent cyclic AMP formation in rat kidney.
Marcus R; Gonzales D
Mech Ageing Dev; 1982 Dec; 20(4):353-60. PubMed ID: 6300573
[TBL] [Abstract][Full Text] [Related]
11. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
12. Biological and immunological properties of tritiated salmon calcitonin.
Wahbe F; Loreau N; Morgat JL; Lajotte C; Kurokawa K; Ardaillou R
Mol Cell Endocrinol; 1977 Sep; 8(3):259-66. PubMed ID: 200509
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic effects of 25(OH)vitamin D3 and peptide hormones on the activation of adenylate cyclase/cyclic AMP system in renal tissue in vitro.
Wald H; Popovtzer MM
Adv Exp Med Biol; 1980; 128():625-33. PubMed ID: 6252764
[No Abstract] [Full Text] [Related]
14. Calcitonin-responsive adenylate cyclase in a calcitonin-producing human cancer cell line.
Hunt NH; Ellison M; Underwood JC; Martin TJ
Br J Cancer; 1977 Jun; 35(6):777-84. PubMed ID: 194616
[TBL] [Abstract][Full Text] [Related]
15. Renal receptors for calcitonin: coordinate occurrence with calcitonin-activated adenylate cyclase.
Marx SJ; Aurbach GD
Endocrinology; 1975 Aug; 97(2):448-53. PubMed ID: 169126
[TBL] [Abstract][Full Text] [Related]
16. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin.
Wookey PJ; Tikellis C; Du HC; Qin HF; Sexton PM; Cooper ME
Am J Physiol; 1996 Feb; 270(2 Pt 2):F289-94. PubMed ID: 8779889
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone receptors of renal cortex: specific binding of biologically active, 125I-labeled hormone and relationship to adenylate cyclase activation.
Di Bella FP; Dousa TP; Miller SS; Arnaud CD
Proc Natl Acad Sci U S A; 1974 Mar; 71(3):723-6. PubMed ID: 4362630
[TBL] [Abstract][Full Text] [Related]
18. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo.
Feyen JH; Cardinaux F; Gamse R; Bruns C; Azria M; Trechsel U
Biochem Biophys Res Commun; 1992 Aug; 187(1):8-13. PubMed ID: 1325797
[TBL] [Abstract][Full Text] [Related]
19. Biologically active, derivatizable salmon calcitonin analog: design, synthesis, and applications.
D'Santos CS; Nicholson GC; Moseley JM; Evans T; Martin TJ; Kemp BE
Endocrinology; 1988 Sep; 123(3):1483-8. PubMed ID: 2841096
[TBL] [Abstract][Full Text] [Related]
20. Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells.
Schneider HG; Raue F; Koppold A; Ruf W; Ziegler R
Acta Endocrinol (Copenh); 1993 Apr; 128(4):373-8. PubMed ID: 8388616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
